NCT00316199 - Efficacy Study of Gemcitabine-Paclitaxel to Treat Metastatic Breast Cancer | Biotech Hunter

Enrollment

60

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

April 30, 2008

Study Completion Date

April 30, 2008

Conditions

Metastatic Breast Cancer

Interventions

DRUG

gemcitabine

1250 mg/m2, intravenous (IV), day 1 and day 8 every 21 days until disease progression

DRUG

paclitaxel

175 mg/m2, intravenous (IV), every 21 days until disease progression

Trial Locations (3)

100071

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Beijing

200032

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Shanghai

510060

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Guangzhou